StockNews.com assumed coverage on shares of Trevena (NASDAQ:TRVN – Get Rating) in a research report sent to investors on Friday morning. The brokerage issued a sell rating on the biopharmaceutical company’s stock. A number of other analysts also recently issued reports on the company. HC Wainwright cut their price objective on Trevena from $11.00 to […]